Correction: UBE2T knockdown inhibits gastric cancer progression

Changjiang Luo; Yunyi Yao; Zeyuan Yu; Huinian Zhou; Lingyun Guo; Junqiang Zhang; Hongtai Cao; Genyuan Zhang; Yumin Li; Zuoyi Jiao

doi:10.18632/oncotarget.28356

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: UBE2T knockdown inhibits gastric cancer progression

PDF | How to cite

Oncotarget. 2023; 14:188-189. https://doi.org/10.18632/oncotarget.28356

Metrics: PDF 878 views | ?

Changjiang Luo^1,*, Yunyi Yao^2,*, Zeyuan Yu¹, Huinian Zhou¹, Lingyun Guo¹, Junqiang Zhang¹, Hongtai Cao¹, Genyuan Zhang¹, Yumin Li¹ and Zuoyi Jiao¹

¹Department of General Surgery, Lanzhou University Second Hospital and Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou, Gansu, 730030, China
²Department of Medical Technology and Key Laboratory of Biotechnology for Laboratory Medicine of Suzhou, Suzhou Vocational Health College, Suzhou, Jiangsu, 215009, China
^*These authors contributed equally to this work

Published: March 11, 2023

Copyright: © 2023 Luo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4C, in the SGC-7901 panel, the first image in the first row is an accidental duplicate of the third image in the second row. The corrected Figure 4, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:32639–32654. DOI: https://doi.org/10.18632/oncotarget.15947

Figure 4: Suppression of UBE2T inhibits growth and colony formation in gastric cancer cells. (A) Cellomics detection indicated that SGC-7901 cell proliferation decreased after suppression of UBE2T. Data are presented as means ± SD. (B) MTT assays in SGC-7901 cells indicated that suppression of UBE2T inhibited SGC-7901 cell proliferation. Data are presented as means ± SD. (C) The tumor colony formation assay indicated that suppression of UBE2T inhibited tumor colony formation in SGC-7901 and BGC-823 cells. Data are presented as the means ± SD. **P < 0.01 versus the control group. (D) The percentages of cells in the G1, S, and G2/M phases were determined using FCM. G1 and S phase populations decreased while the G2/M phase population increased in SGC-7901 and BGC-823 cells. Data are presented as means ± SD. **P < 0.01 versus the control group. (E) Annexin V staining was measured using FCM to evaluate apoptosis. The percentage of apoptotic SGC-7901 and BGC-823 cells increased dramatically after siRNA lentivirus infection. Data are presented as means ± SD. **P < 0.01 versus the control group.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28356

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: UBE2T knockdown inhibits gastric cancer progression